Tammy M. Martin

Dr. Tammy M. Martin

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2009 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
TMTammy M. Martin
Tammy M. Martin
ZZZili Zhang
Zili Zhang
PKPaul Kurz
Paul Kurz
CRCarlos D. Rosé
Carlos D. Rosé
HCHong Chen
Hong Chen
JRJames T. Rosenbaum
James T. Rosenbaum
Objective: Blau syndrome is a rare, autosomal‐dominant, autoinflammatory disorder characterized by granulomatous arthritis, uveitis, and dermatitis. Genetics studies have shown that the disease is caused by single nonsynonymous substitutions in NOD‐2, a member of the NOD‐like receptor or NACHT–leucine‐rich repeat (NLR) family of intracellular proteins. Several NLRs function in the innate immune system as sensors of pathogen components and participate in immune‐mediated cellular responses via the caspase 1 inflammasome. Mutations in a gene related to NOD‐2, NLRP3, are responsible for excess caspase 1–dependent interleukin‐1β (IL‐1β) in cryopyrinopathies such as Muckle‐Wells syndrome. Furthermore, functional studies demonstrate that caspase 1–mediated release of IL‐1β also involves NOD‐2. The aim of this study was to test the hypothesis that IL‐1β may mediate the inflammation seen in patients with Blau syndrome.Methods: IL‐1β release was measured in peripheral blood mononuclear cells cultured in vitro, obtained from 5 Blau syndrome individuals with a NOD2 (CARD15) mutation.Results: We observed no evidence for increased IL‐1β production in cells obtained from subjects with Blau syndrome compared with healthy control subjects. Furthermore, we presented 2 cases of Blau syndrome in which recombinant human IL‐1 receptor antagonist (anakinra) was ineffective treatment.Conclusion: Taken together, these data suggest that in contrast to related IL‐1β–dependent autoinflammatory cryopyrinopathies, Blau syndrome is not mediated by excess IL‐1β or other IL‐1 activity.

1 July 2002 in Current Opinion in Rheumatology
Verified
Journal Article
Closed access
TMTammy M. Martin
Tammy M. Martin
JSJustine R. Smith
Justine R. Smith
JRJames T. Rosenbaum
James T. Rosenbaum
Anterior uveitis describes inflammation that involves the iris or ciliary body. Anterior uveitis may be part of a systemic illness such as a spondyloarthropathy. It may also arise from an infection such as herpes simplex; be part of an ocular syndrome, such as Fuchs' heterochromic iridocyclitis; be part of trauma, as in cataract surgery; or result from an idiopathic eye disease with a presumed immune pathogenesis. During 2001, progress has been made understanding uveitis in general, as well as specifically, in association with spondyloarthropathy. Here, we review recent insights into anterior uveitis with regard to clinical presentation, immune mechanisms, genetics, and anti-tumor necrosis factor therapy.

9 November 2009 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
SSSrilakshmi M Sharma
Srilakshmi M Sharma
DCDongseok Choi
Dongseok Choi
SPStephen R Planck
Stephen R Planck
CHChristina A Harrington
Christina A Harrington
CACarrie R Austin
Carrie R Austin
JRJames T Rosenbaum
James T Rosenbaum
Introduction: Axial spondyloarthropathy (SpA) is a group of inflammatory diseases, with ankylosing spondylitis as the prototype. SpA affects the axial skeleton, entheses, joints and, at times, the eyes. This study tested the hypothesis that SpA is characterized by a distinct pattern of gene expression in peripheral blood of affected individuals compared with healthy controls. Methods: High-density, human GeneChip® probe arrays were used to profile mRNA of peripheral blood cells from 18 subjects with SpA and 25 normal individuals. Samples were processed as two separate sets at different times (11 SpA + 12 control subjects in primary set (Set 1); 7 SpA+ 13 control subjects in the validation set (Set 2)). Blood samples were taken at a time when patients were not receiving systemic immunomodulatory therapy. Differential expression was defined as a 1.5-fold change with a q value < 5%. Gene ontology and pathway information were also studied. Results: Signals from 134 probe sets (representing 95 known and 12 unknown gene transcripts) were consistently different from controls in both Sets 1 and 2. Included among these were transcripts for a group of 20 genes, such as interleukin-1 (IL-1) receptors 1 and 2, Nod-like receptor family, pyrin domain containing 2 (NLRP2), secretory leukocyte peptidase inhibitor (SLPI), secreted protein acidic and rich in cysteine (SPARC), and triggering receptor expressed on myeloid cells 1 (TREM-1) that are clearly related to the immune or inflammatory response and a group of 4 transcripts that have a strong role in bone remodeling. Conclusions: Our observations are the first to implicate SPARC, SLPI, and NLRP2, a component of the innate immune system, in the pathogenesis of SpA. Our results also indicate a possible role for IL-1 and its receptors in SpA. In accord with the bone pathology component of SpA, we also found that expression levels of transcripts reflecting bone remodeling factors are also distinguishable in peripheral blood from patients with SpA versus controls. These results confirm some previously identified biomarkers implicated in the pathogenesis of SpA and also point to novel mediators in this disease.

7 January 2005 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
TMTammy M. Martin
Tammy M. Martin
GZGe Zhang
Ge Zhang
JLJingchun Luo
Jingchun Luo
LJLi Jin
Li Jin
TDTrudy M. Doyle
Trudy M. Doyle
JRJohn D. Reveille
John D. Reveille
Objective: Uveitis or intraocular inflammation is a major cause of visual loss. Acute anterior uveitis (AAU) affects ∼40% of patients with ankylosing spondylitis (AS) but also affects patients with no evidence of spondylarthritis. We sought to determine whether a unique genetic region could be implicated in a specific manifestation—AAU—of a multisystem, inflammatory, genetically complex disease, AS.Methods: Individuals from families multiplex for AAU were genotyped at 400 markers representing the ABI PRISM linkage map MD‐10, and at the HLA–B, DRB1, DQA1, DQB1, and DPB1 alleles. Among the family members with AAU, 76 affected sibpairs were analyzed (6 without concomitant AS, 12 discordant for AS, and 58 concordant for AS). Two‐point and multipoint nonparametric linkage analyses were performed, and 1‐parameter allele‐sharing model logarithm of odds (LOD) scores were determined.Results: As previously reported for AS, linkage at the major histocompatibility complex region (chromosome 6p21) was evident, exhibiting the highest multipoint LOD score (4.96 at marker HLA–B). Strong linkage was seen at a region on chromosome 9p21–9p24, with a LOD score of 3.72 at marker D9S157. When compared with a companion cohort of AS families, the linkage at this region was found in association with AAU but not with AS. A third region on chromosome 1q23–1q31 was observed to have suggestive linkage (LOD 2.05 at marker D1S238), which overlaps with a region associated with AS.Conclusion: This is the first study in which a genetic region for AAU has been identified by genome‐wide scan. Even though AS was highly prevalent in this cohort of families, a locus at chromosome 9p21–9p24 was identified that uniquely associates with AAU. Identifying the genetic perturbation at this region may advance our understanding of the mechanisms involved in tissue‐specific pathology of complex inflammatory diseases.

1 November 2003 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
TMTammy M. Martin
Tammy M. Martin
TDTrudy M Doyle
Trudy M Doyle
JSJustine R. Smith
Justine R. Smith
DDDenis Dinulescu
Denis Dinulescu
KRKristal Rust
Kristal Rust
JRJames T Rosenbaum
James T Rosenbaum

Verified
Open access
PDF file
HKHyun Soo Kim
Hyun Soo Kim
DCDongseok Choi
Dongseok Choi
LLLyndell Lim
Lyndell Lim
GAGopal Allada
Gopal Allada
JSJustine R. Smith
Justine R. Smith
TMTammy M. Martin
Tammy M. Martin
Interleukin 23 receptor (IL23R) gene has been reported as a genetic factor strongly associated with inflammatory bowel disease, psoriasis, and ankylosing spondylitis. We investigated the association between IL23R gene single nucleotide polymorphisms (SNPs) and susceptibility to sarcoidosis, including the clinical manifestation of uveitis.Ninety-one sarcoidosis subjects (58 with and 33 without uveitis) and 104 healthy controls were genotyped for eleven IL23R SNPs. DNA was amplified using specific PCR primers and genotyped by denaturing HPLC and/or direct DNA sequencing. Case-control frequency comparisons were analyzed using Chi square test.Three IL23R SNPs, rs7517847 (intron 6), rs11465804 (intron 8), and rs11209026 (exon 9, c.1142G>A, p.Arg381Gln) were associated with sarcoidosis in our population (p < 0.05): rs7517847 showed increased frequencies in sarcoidosis compared to controls, but rs11465804 and rs11209026 were decreased. Two of these SNPs were associated with the uveitis subgroup compared to controls: rs11465804 (0.9% vs. 7.2%, OR = 0.11, P = 0.013) and rs11209026 (1.8% vs. 7.3%, OR = 0.23, P = 0.038).This finding indicates the association of IL23R polymorphism with sarcoidosis, especially with sarcoid uveitis. IL23R may be a common susceptibility gene shared by several autoimmune disorders including inflammatory bowel disease, psoriasis, and ankylosing spondylitis and sarcoid uveitis.